Patients: This Phase II study involved 40 patients with malignant pleural mesothelioma. Thirty-four patients were men, and six were women. The median age was 62 years. All but one patient was exposed to asbestos. Twenty-five patients had stage 3 or 4 disease. Twenty patients had received prior chemotherapy, radiotherapy, or surgery.
Treatment: The treatment consisted of one biologic agent: thalidomide. Thalidomide is thought to be an anti-angiogenesis agent that helps stop new blood vessels from forming.
Toxicities: Grade 2-3 toxicities included an allergic reaction, neurotoxicity, and constipation.
Results: The median survival was 7.6 months (230 days).
DISCLAIMER: The following is a summary of some of the terms & conditions for accessing the information on this website. It is provided for convenience only. For the full terms & conditions please click here. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional medical advice, examination, diagnosis or treatment. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. This website provides links to other websites for convenience only. Cancer Monthly is not responsible for the availability or content of these external websites, nor does Cancer Monthly endorse, warrant or guarantee the products, services or information described or offered at these other websites.